Which of the following substances is prohibited from being dispensed under a collaborative practice agreement?

The prohibition against dispensing certain substances under a collaborative practice agreement primarily stems from regulatory provisions intended to ensure safe and effective medication management. Schedule I controlled substances are deemed to have no accepted medical use and a high potential for abuse, leading to their complete prohibition from being dispensed in any circumstance, including under collaborative practice agreements. Therefore, they cannot be prescribed or dispensed by healthcare professionals operating under such agreements.

Schedule II controlled substances, while permitted for use in specific clinical contexts, still require careful oversight due to their high potential for abuse and dependency. Similarly, Schedule III controlled substances, though less strictly regulated, are still classified with some restrictions in mind.

The inclusion of all these schedules in the prohibition aligns with the overarching objective of ensuring patient safety and limiting the potential for misuse of controlled substances. By not permitting any form of dispensing of these substances under collaborative practice agreements, regulations emphasize the importance of strict adherence to guidelines regarding controlled substances in both prescription and dispensing practices.